Serefarm (Inhalation Powder)
Prescription dry powder inhaler for long-term respiratory management
Serefarm is a prescription inhalation powder supplied in pre-dispensed doses of 50 micrograms and 100 micrograms per inhalation. It is delivered via a dry powder inhaler (DPI) and is intended for the long-term maintenance of respiratory conditions. Because Serefarm is a preventer rather than a rescue medicine, it should be taken regularly at consistent times, not only when symptoms appear. This evidence-based guide explains how Serefarm works, how to use the inhaler correctly, and what you should know about dosage, interactions, side effects, and storage.
Quick Facts
Key Takeaways
- Serefarm is a prescription-only dry powder inhaler supplied in two strengths: 50 micrograms and 100 micrograms per pre-dispensed dose.
- It is designed for regular, long-term use in respiratory maintenance therapy — it is not intended as a rescue inhaler for sudden breathing difficulties.
- Correct inhaler technique is critical: dry powder inhalers require a fast, deep inhalation to disperse the powder from the device into the lungs.
- Always follow the prescribing information and your clinician’s instructions. The strength, number of daily doses, and combination with other inhalers is individualised for each patient.
- Contact a healthcare professional promptly if your breathing worsens, if you need rescue medication more often than usual, or if you experience symptoms such as chest pain, severe palpitations, or signs of an allergic reaction.
What Is Serefarm and What Is It Used For?
Serefarm is a dry powder inhaler (DPI) product formulated as an inhalation powder with pre-dispensed (single-dose) strengths of 50 micrograms and 100 micrograms per actuation. Dry powder inhalers deliver the medicine as fine, micronised particles that are drawn into the lungs when the patient inhales forcefully through the mouthpiece. Unlike pressurised metered-dose inhalers (pMDIs), DPIs do not use a propellant gas and do not require coordination between pressing a canister and breathing in. This makes them a useful option for many patients, particularly those who find pMDIs technically difficult.
Inhaled medicines are a cornerstone of modern respiratory care because they deliver the active substance directly to the site of action — the airways — while limiting systemic exposure. This targeted delivery means that lower total doses can achieve meaningful clinical effects, with a generally lower burden of systemic side effects compared with oral formulations. International guidelines from the GINA initiative for asthma and the GOLD initiative for COPD place inhaled maintenance therapy at the heart of stepwise disease management. Whether the goal is to reduce airway inflammation, relax bronchial smooth muscle, or both, inhaled medicines are usually preferred over systemic drugs when a suitable option is available.
Serefarm is classified as a maintenance (preventer) inhaler. Maintenance inhalers are taken regularly every day, even when you feel well, to keep the airways stable and reduce the risk of symptom flare-ups. This is fundamentally different from a rescue (reliever) inhaler, which is used only as needed to relieve sudden breathlessness, wheezing, or chest tightness. Patients who are prescribed a maintenance inhaler such as Serefarm will typically also be given a separate, fast-acting rescue inhaler. The two inhalers are not interchangeable, and it is important to understand which device does which job.
The availability of Serefarm in two strengths — 50 micrograms and 100 micrograms per dose — allows clinicians to tailor therapy to the severity of the underlying respiratory condition, the patient’s age, and their individual response to treatment. Lower strengths may be appropriate for initial therapy or for patients with mild disease, while higher strengths are typically reserved for those with more persistent symptoms, measurable airflow limitation, or a history of exacerbations. The choice of strength and the daily dosing regimen are medical decisions and should not be adjusted without discussing them with the prescriber.
Like all inhaled respiratory products, Serefarm works best when used consistently and with good inhaler technique. Studies across the full range of inhaler devices repeatedly show that a significant proportion of patients do not achieve optimal drug deposition in the lungs because of small, correctable errors in technique. For that reason, it is essential to review the patient information leaflet supplied with the inhaler, to watch instructional videos where available, and to ask your pharmacist, nurse, or doctor to observe your technique at each review visit.
Serefarm is a preventive medicine taken regularly. It is not a rescue inhaler and will not relieve a sudden asthma attack or a sharp worsening of COPD symptoms. Always carry a separate short-acting rescue inhaler, as prescribed, for acute breathing difficulties. If you find yourself using your rescue inhaler more often than usual, or if your breathing worsens despite taking Serefarm as prescribed, contact your doctor urgently — this can be an early sign that your condition needs review.
What Should You Know Before Taking Serefarm?
Contraindications
Serefarm should not be used if you have a known hypersensitivity (allergy) to any of its components. Allergic reactions to inhaled medicines are uncommon but may include skin rash, itching, swelling of the face, lips, or tongue, and, in rare cases, difficulty breathing or a drop in blood pressure. If you have ever had an allergic reaction to a similar inhaled medicine, inform your doctor before starting Serefarm, as some excipients are shared between different inhaled products.
Patients should also avoid initiating Serefarm on their own if the intended indication has not been confirmed by a clinician. Starting a maintenance inhaler without a confirmed diagnosis can mask symptoms of other conditions and delay appropriate treatment. A thorough medical history, physical examination, and often objective tests such as spirometry are needed to confirm an underlying respiratory diagnosis and to justify the long-term use of an inhaled therapy.
Warnings and Precautions
If your breathing symptoms worsen after starting Serefarm, or if you notice that your rescue inhaler is being used more frequently than usual, contact your doctor promptly. Do not simply increase the number of daily puffs of Serefarm without medical advice — your overall treatment plan may need to be re-evaluated. Similarly, once your condition is well controlled, your doctor may consider whether to step down treatment. Any changes to your regular inhaler regimen should always be medically supervised.
Additional caution is needed in patients with specific underlying conditions. Your clinician may decide to monitor you more closely if you have any of the following:
- Cardiovascular disease — including coronary artery disease, uncontrolled high blood pressure, arrhythmias, or a prolonged QT interval on ECG.
- Hyperthyroidism — an overactive thyroid gland, which can amplify cardiovascular side effects of certain inhaled medicines.
- Diabetes mellitus — because some inhaled beta-2 agonists can raise blood glucose, especially at higher doses.
- Low blood potassium (hypokalaemia) — either baseline or due to other medications such as diuretics, theophylline, or systemic corticosteroids.
- Tuberculosis or other chronic lung infections — inhaled corticosteroid components, if present, can influence host defence mechanisms in the lung.
- Liver disease — which may alter the systemic clearance of inhaled medicines and any swallowed portion of the dose.
Do not stop any other prescribed inhalers, corticosteroid tablets, or supporting medicines when you start Serefarm, unless your doctor specifically tells you to. Abruptly stopping corticosteroid therapy can trigger a disease flare or, in some cases, adrenal insufficiency. The safe way to change a chronic respiratory regimen is always to do so gradually and under medical supervision, often with objective reassessment of lung function along the way.
Pregnancy and Breastfeeding
If you are pregnant, planning a pregnancy, or breastfeeding, discuss Serefarm with your doctor before starting or continuing treatment. Decisions about inhaled respiratory medicines during pregnancy should be made on an individual basis, weighing the benefits of controlled disease against any potential risks of the medication. Crucially, uncontrolled asthma or severe COPD exacerbations during pregnancy carry their own significant risks, including low birth weight, prematurity, and maternal hypoxia. International guidelines therefore emphasise that respiratory disease should be optimally controlled throughout pregnancy, and that treatment changes should not be made without medical advice.
For breastfeeding mothers, most inhaled medicines achieve very low systemic concentrations because the lung delivery system minimises absorption. However, specific safety data for Serefarm in breastfeeding should be reviewed with your doctor or pharmacist, and any decision to continue therapy during lactation should be made after weighing the maternal benefit of treatment against the theoretical risk to the infant.
Driving and Operating Machinery
Serefarm is unlikely to have a major impact on the ability to drive or use machines for most patients. Some individuals may experience transient side effects such as tremor, palpitations, or dizziness, particularly during the first days of treatment or after a dose increase. You should be aware of how Serefarm affects you personally before driving or operating complex machinery. If you notice any symptoms that could impair your concentration, coordination, or reaction time, avoid these activities and discuss the symptoms with your doctor.
How Does Serefarm Interact with Other Drugs?
Drug interactions are an important consideration for any long-term inhaled therapy. Although inhaled dosing generally produces lower systemic exposure than oral dosing, some medicines can still interact with ingested fractions of the dose, influence drug metabolism, or produce additive effects on the heart, electrolytes, or airway smooth muscle. Always provide your doctor and pharmacist with an up-to-date medication list, including prescription drugs, over-the-counter remedies, and herbal or nutritional supplements, so that potential interactions can be identified before they cause harm.
Major Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance |
|---|---|---|
| Non-selective beta-blockers (e.g. propranolol, sotalol, timolol) | Pharmacological antagonism | May block or significantly reduce the bronchodilator effect of inhaled beta-2 agonists. Generally avoided in patients with reversible airway disease. |
| Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, cobicistat) | Inhibition of drug metabolism | Can substantially raise systemic exposure to medicines metabolised by CYP3A4, including the swallowed portion of inhaled doses. Combination may be contraindicated or require specialist oversight. |
| Medicines that prolong the QT interval (e.g. certain antiarrhythmics, macrolides, fluoroquinolones) | Additive cardiac effect | Combining QT-prolonging medicines with high-dose beta-2 agonists may increase the risk of serious arrhythmias. ECG monitoring may be indicated in high-risk patients. |
| Other long-acting inhaled bronchodilators | Duplicate therapy | Using two long-acting bronchodilators of the same class together provides no additional benefit and increases the risk of side effects such as tremor and palpitations. |
Non-selective beta-blockers are one of the most clinically relevant interactions for inhaled respiratory therapy. Because these drugs block the same beta-2 receptors that many maintenance inhalers activate, they can significantly reduce or even abolish the bronchodilator effect. For patients with a history of asthma or reactive airways, cardioselective beta-blockers are generally preferred when a beta-blocker is truly necessary, and the combination must be carefully monitored. Always inform any cardiologist, ophthalmologist, or other specialist who may consider prescribing a beta-blocker that you use an inhaled respiratory medicine.
Other Interactions to Be Aware Of
| Drug / Drug Class | Interaction Type | Clinical Significance |
|---|---|---|
| Diuretics (e.g. furosemide, hydrochlorothiazide) | Additive hypokalaemia | Both groups can lower serum potassium; monitoring of potassium levels is advisable, especially in patients with cardiac disease or on higher inhaler doses. |
| Theophylline | Additive hypokalaemia | Xanthine derivatives combined with beta-2 agonists may further reduce potassium levels. Periodic blood tests may be required. |
| Systemic corticosteroids | Additive hypokalaemia and metabolic effects | Prolonged or high-dose oral corticosteroids alongside inhaled beta-2 agonists can reduce potassium and influence glucose control. |
| Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants | Additive cardiovascular effects | May potentiate the cardiovascular effects of beta-2 agonists. Use with caution and only under medical supervision. |
| Halogenated anaesthetic agents | Additive cardiac sensitisation | Patients undergoing general anaesthesia should inform their anaesthetist about any inhaled maintenance therapy. A brief pause before surgery may be considered. |
Hypokalaemia (low blood potassium) is a potential class effect of beta-2 agonists that can be amplified when combined with other potassium-lowering medicines. Clinically, hypokalaemia can cause muscle weakness, cramps, and heart rhythm disturbances. In patients with underlying cardiac disease or who are taking diuretics, theophylline, or systemic corticosteroids alongside an inhaler, periodic monitoring of serum potassium levels may be recommended. If you are scheduled for surgery, an ECG, or a hospital admission, remember to mention all your inhalers so that electrolyte and cardiac effects can be anticipated and managed.
What Is the Correct Dosage of Serefarm?
The general principle of maintenance inhaler therapy is to use the lowest effective dose that keeps the condition well controlled. This minimises the risk of side effects while ensuring that the airways remain stable. Your doctor will typically start you on a dose appropriate for the severity of your symptoms, monitor your response over several weeks, and then step the dose up or down as needed. Regular review — at least every 6 to 12 months — is recommended to confirm that the chosen regimen is still appropriate.
Adults and Adolescents
Standard Maintenance Dosing
Typical regimen: 1 inhalation twice daily of either the 50 microgram or 100 microgram strength, taken approximately 12 hours apart.
The prescriber may start at the 50 microgram strength and step up to the 100 microgram strength if symptom control is incomplete, or begin directly at the higher strength in more severe disease. Doses above those recommended in the prescribing information should not be used without specialist advice.
Severe or Poorly Controlled Disease
For patients whose symptoms are not well controlled on the standard regimen, the prescriber may either increase the strength, add a complementary controller medicine, or refer the patient to a respiratory specialist. A persistent need for more than the prescribed dose is usually a signal that the overall treatment plan requires review rather than simple dose escalation.
Children
Paediatric Use
Use of Serefarm in children should be guided by the specific age limits and paediatric dosing described in the prescribing information and by a paediatric respiratory specialist. Children may require a spacer or alternative device depending on their inspiratory flow, as dry powder inhalers rely on a sufficiently strong inhalation to deliver the full dose. Parents and carers should always watch the child use the device under supervision, especially during the first weeks of therapy.
Elderly Patients
Older adults can usually take the standard adult dose of Serefarm, but they may be more susceptible to cardiovascular side effects such as palpitations and tremor, particularly if they also have ischaemic heart disease, heart failure, or arrhythmias. Polypharmacy is common in older patients, so the potential for drug interactions should be carefully reviewed at every prescription and pharmacy encounter. Cognitive or dexterity limitations can also affect inhaler technique, and a spacer or alternative device may be considered in those circumstances.
How to Use the Inhaler
Correct technique is as important as the chosen dose. Research consistently shows that a substantial proportion of patients use their inhalers incorrectly, reducing the amount of drug that reaches the lungs. A pharmacist, respiratory nurse, or physician should demonstrate the technique and observe it periodically to make sure that your inhalation is optimal. The general sequence for a dry powder inhaler is summarised below, but you should always follow the specific instructions printed in the package leaflet for Serefarm, which may contain additional device-specific steps.
- Prepare the device: Hold the inhaler upright and open or activate it according to the leaflet so that one pre-dispensed dose is loaded. Do not tilt or shake it once a dose is prepared, unless the leaflet specifies otherwise.
- Breathe out away from the inhaler: Exhale gently and fully, turning your face away from the mouthpiece. Never breathe out into the device — moisture from your breath can clump the powder.
- Seal your lips around the mouthpiece: Place the mouthpiece between your teeth and close your lips firmly around it without biting. Keep your tongue flat.
- Inhale quickly and deeply: Take a single, forceful, deep breath through your mouth. A dry powder inhaler depends on your own inspiratory effort to disperse the medicine, so a slow, gentle breath will not deliver the full dose.
- Hold your breath: Remove the inhaler from your mouth and hold your breath for about 5 to 10 seconds, or as long as comfortable, allowing the powder to settle in the airways before exhaling slowly.
- Close the device: Close the inhaler to protect the next dose from moisture. If your doctor has prescribed two inhalations, repeat from step 1 after a short pause.
- Rinse your mouth if instructed: If Serefarm contains a corticosteroid component or if your pharmacist recommends it, rinse your mouth with water and spit it out after use to reduce the risk of oral thrush and hoarseness.
You may not always feel or taste a dose from a dry powder inhaler, and this is normal. What matters is the correct technique and the dose counter (where available) confirming that a dose has been delivered. If you are unsure whether a dose has been taken, do not take an extra inhalation — continue with the next scheduled dose as usual and ask your pharmacist to review your technique.
Missed Dose
If you forget to take a dose of Serefarm, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose entirely and continue with your usual regimen. Do not take a double dose to compensate for a forgotten one, as this increases the risk of side effects such as palpitations, tremor, and headache. Using a pill organiser, a phone reminder, or linking the dose to a routine event (such as brushing your teeth) can help you build a consistent habit.
Overdose
If you accidentally take more Serefarm than prescribed, you may notice a faster or irregular heartbeat, muscle shaking, nervousness, headache, nausea, or muscle cramps. These symptoms are usually self-limiting but can be uncomfortable. In case of significant overdose — especially if a child has accidentally used the device — seek medical advice immediately. Contact your local poison control centre or emergency department for guidance. Treatment is mainly supportive; cardiac monitoring may be performed in hospital, and specific medications may be considered in severe cases under specialist supervision.
What Are the Side Effects of Serefarm?
As with all medicines, Serefarm can cause side effects, although not everyone who uses it will experience them. Most reported effects are predictable consequences of inhaled respiratory therapy and tend to diminish after the first days or weeks as the body adapts to treatment. The categories below are based on the standard frequency ranges used in European and international drug labelling. These ranges describe the proportion of patients expected to experience a given effect, based on clinical trials and post-marketing surveillance of inhaled medicines in this class.
Very Common
May affect more than 1 in 10 people
- Headache, particularly during the first days of treatment
- Throat irritation or a sensation of something in the throat
Common
May affect up to 1 in 10 people
- Tremor, especially of the hands
- Palpitations or awareness of the heartbeat
- Hoarseness (dysphonia)
- Oral candidiasis (thrush) if the inhaler contains a corticosteroid component — rinse your mouth after use to reduce the risk
- Muscle cramps
Uncommon
May affect up to 1 in 100 people
- Skin rash or itching
- Tachycardia (rapid heart rate), more common at higher doses
- Nervousness, restlessness, or feeling anxious
- Dizziness
Rare
May affect up to 1 in 1,000 people
- Sleep disturbance and insomnia
- Hypokalaemia (low blood potassium), which may cause irregular heartbeat, muscle weakness, or cramps
- Raised blood glucose, particularly relevant in patients with diabetes
- Behavioural changes, including restlessness or agitation, more commonly seen in children
Very Rare
May affect up to 1 in 10,000 people
- Paradoxical bronchospasm — sudden worsening of wheezing or breathlessness immediately after inhalation. Stop using Serefarm, use your rescue inhaler, and seek urgent medical attention.
- Cardiac arrhythmias, including atrial fibrillation, supraventricular tachycardia, and extrasystoles
- Severe allergic reactions (anaphylaxis) — sudden difficulty breathing, swelling of the face or throat, severe rash, or a drop in blood pressure. Call emergency services immediately.
- Chest pain, joint pain, or nausea
Stop using Serefarm and seek emergency medical care if you experience: sudden worsening of breathing immediately after inhalation (paradoxical bronchospasm), swelling of the face, lips, tongue, or throat, severe rash or itching, chest pain, fainting, or any symptoms of a severe allergic reaction. If your usual rescue inhaler is not relieving your symptoms, call your local emergency number at once.
The tremor and palpitations associated with inhaled beta-2 agonists are pharmacological effects of beta-2 receptor stimulation and are generally dose-related. They are most commonly reported in the first days or weeks of treatment, or after a dose increase, and usually diminish over time as tolerance develops. If these symptoms are persistent or bothersome, your doctor may consider adjusting the dose, spacing the doses differently, or re-evaluating the overall regimen. Do not ignore persistent symptoms — early communication with your prescriber allows small adjustments before treatment becomes difficult to tolerate.
Because ongoing pharmacovigilance is essential for the safety of medicines, you should report any side effects to your doctor, pharmacist, or national medicines authority. Even effects that seem minor can provide useful information about the real-world profile of a medicine when enough reports are combined. This is particularly important for newer products and less common patient groups, for which the clinical trial database may be limited.
How Should You Store Serefarm?
Proper storage is especially important for dry powder inhalers, where exposure to humidity can clump the powder and compromise dose delivery. The medicine is only effective if it reaches the lungs in the correct particle-size distribution, so protecting it from moisture and temperature extremes is an essential part of safe use. The following general principles apply to most DPI products, including Serefarm — always also follow any specific instructions in the package leaflet supplied with your inhaler.
- Temperature: Store at the temperature range stated in the package leaflet, generally below 25 to 30 degrees Celsius. Do not refrigerate or freeze.
- Humidity: Keep the device in its original packaging and closed when not in use. Avoid storing it in the bathroom, kitchen, or other humid environments.
- Light: Protect from prolonged direct sunlight and from heat sources such as radiators or car dashboards.
- Device integrity: Do not drop, disassemble, or attempt to clean the device other than as instructed. Do not immerse in water.
- Children: Always keep inhalers out of the sight and reach of children. Accidental activation can lead to inhalation of an unintended dose.
- Expiry date: Do not use the device after the expiry date printed on the carton or label. The expiry date usually refers to the last day of the month shown.
- Disposal: Do not dispose of inhalers in household waste or wastewater. Return unused or expired devices to your pharmacist for proper disposal.
When travelling, keep the inhaler in your hand luggage so that it remains at cabin temperature and is readily available. Rapid changes in altitude and temperature do not usually affect dry powder inhalers as much as pressurised inhalers, but exposure to freezing baggage holds or hot vehicle interiors should still be avoided. If you travel across time zones, plan your dosing schedule carefully to maintain regular dosing intervals as far as possible.
What Does Serefarm Contain?
Serefarm is presented as a pre-dispensed inhalation powder, which means that each dose is individually metered within the device. This design provides consistent dose delivery and avoids the need for the patient to measure out a dose manually. The pre-dispensed format also makes it easier to track remaining doses, especially when the device includes a dose counter.
- Active substance: Serefarm, in strengths of 50 micrograms and 100 micrograms per pre-dispensed dose.
- Excipients: As with most dry powder inhalers, Serefarm is likely to contain a carrier excipient such as lactose monohydrate to aid dose delivery. The full list of excipients is specified in the package leaflet supplied with your device.
Many dry powder inhalers use lactose monohydrate as a carrier. This may contain trace amounts of milk protein, which in extremely rare cases has been associated with allergic-type reactions in patients with severe milk protein allergy. The amount of lactose is very small and is usually well tolerated even by people with lactose intolerance. If you have a documented milk protein allergy, inform your doctor so that an alternative formulation can be considered. Always check the specific excipient list for Serefarm in the enclosed package leaflet.
Dry powder inhalers do not contain the pressurised propellant gases found in pMDIs. This means that DPI products generally have a lower environmental footprint than equivalent pressurised inhalers, because they avoid the use of hydrofluoroalkane (HFA) propellants, which have a high global warming potential. Environmental considerations are increasingly relevant in respiratory medicine, and many clinical guidelines now include the environmental impact of inhaler choice as a factor to discuss with patients.
Frequently Asked Questions About Serefarm
Serefarm is a prescription inhalation powder delivered via a dry powder inhaler in pre-dispensed doses of 50 micrograms and 100 micrograms. It is prescribed for the long-term maintenance of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), where regular, daily airway control is needed. It is not a rescue inhaler and is not intended for immediate relief of sudden breathing difficulties.
Serefarm is a preventer (maintenance) inhaler. Its role is to maintain stable airway function when used regularly every day at the prescribed times. It is not a rescue inhaler. For sudden symptoms such as wheezing, breathlessness, or a severe cough, you should use the short-acting rescue inhaler prescribed for that purpose. If you need your rescue inhaler more often than usual, contact your doctor as soon as possible — this can be an early warning sign of worsening disease control.
Maintenance inhalers such as Serefarm are designed to build up stable airway control over days to weeks of regular use. You may notice some improvement shortly after starting, but the main benefit comes from consistent daily dosing that keeps the airways settled and reduces the frequency and severity of symptoms. It is essential to continue treatment as prescribed even when you feel well, because stopping a maintenance inhaler abruptly can trigger a flare-up of the underlying condition.
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate, as this can increase the risk of side effects. Setting a reminder on your phone or linking the dose to a daily routine — such as brushing your teeth — can make it easier to stay on schedule.
If you are pregnant, planning a pregnancy, or breastfeeding, consult your doctor before using or continuing Serefarm. Your doctor will weigh the benefits of stable respiratory control against any potential risks. Importantly, uncontrolled asthma or COPD during pregnancy can also pose serious risks to both mother and baby, including premature birth and low birth weight, so treatment should not be stopped without medical advice. International guidelines emphasise that respiratory disease should be optimally controlled throughout pregnancy.
It is common for patients with respiratory conditions to use more than one inhaler, such as a maintenance inhaler together with a separate rescue inhaler, or combinations of different long-acting controllers. However, combining inhalers should always be done under medical supervision. Using two inhalers from the same class at the same time generally provides no extra benefit and increases side effects. Always show your doctor and pharmacist the full list of inhalers you use, including devices prescribed by different specialists, so that your regimen can be coordinated.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2024 Report.
- European Medicines Agency (EMA). Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP). EMA Committee for Medicinal Products for Human Use.
- British National Formulary (BNF). Inhaled drugs for airway disease. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- British Thoracic Society (BTS) / Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma, 2019 Update.
- Cazzola M, et al. Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews. 2012;64(3):450–504. doi:10.1124/pr.111.004580
- Laube BL, et al. What the pulmonary specialist should know about the new inhalation therapies. European Respiratory Journal. 2011;37(6):1308–1331. doi:10.1183/09031936.00166410
- Price D, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respiratory Medicine. 2013;107(1):37–46. doi:10.1016/j.rmed.2012.09.017
- Usmani OS, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respiratory Research. 2018;19:10. doi:10.1186/s12931-017-0710-y
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in pulmonology, respiratory medicine, and clinical pharmacology. All content follows international clinical guidelines (GINA, GOLD, BTS/SIGN, ERS/ATS) and the GRADE evidence framework.
Written by specialist physicians with expertise in respiratory medicine and inhaled therapies, based on the approved Summary of Product Characteristics and international clinical guidelines.
Independently reviewed by the iMedic Medical Review Board to ensure accuracy, completeness, and adherence to evidence-based medicine standards.
Evidence Level 1A where available, based on systematic reviews and meta-analyses of randomised controlled trials. All claims referenced to peer-reviewed sources.
No pharmaceutical company funding, sponsorship, or advertising. All content is independently produced without commercial influence or conflict of interest.
Meet the full iMedic Medical Team | Read our Editorial Standards